

Radioligand Therapy Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/R28FE6FC27EAEN.html>

Date: April 2022

Pages: 60

Price: US\$ 3,250.00 (Single User License)

ID: R28FE6FC27EAEN

Abstracts

This report contains market size and forecasts of Radioligand Therapy in Global, including the following market information:

Global Radioligand Therapy Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Radioligand Therapy market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Actinium 225 (Ac-225) Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Radioligand Therapy include Novartis, Advanced Accelerator Applications, Mercy Radiology, POINT Biopharma Global Inc, Fusion Pharma, Telix Pharmaceuticals Ltd, Lantheus Holdings, Inc, Bayer AG and Curium Pharma and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Radioligand Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Radioligand Therapy Market, by Used Radionuclides, 2017-2022, 2023-2028 (\$ millions)

Global Radioligand Therapy Market Segment Percentages, by Used Radionuclides, 2021 (%)

Actinium 225 (Ac-225)

Lutetium 177 (Lu-177)

Gallium 68 (Ga-68)

Fluorine 18 (F-18)

Other Radionuclides

Global Radioligand Therapy Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Radioligand Therapy Market Segment Percentages, by Application, 2021 (%)

Neuroendocrine Neoplasms

Prostate Cancer

Global Radioligand Therapy Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Radioligand Therapy Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Radioligand Therapy revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Radioligand Therapy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Novartis

Advanced Accelerator Applications

Mercy Radiology

POINT Biopharma Global Inc

Fusion Pharma

Telix Pharmaceuticals Ltd

Lantheus Holdings, Inc

Bayer AG

Curium Pharma

Precirix

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Radioligand Therapy Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Used Radionuclides
 - 1.2.2 Market by Application
- 1.3 Global Radioligand Therapy Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL RADIOLIGAND THERAPY OVERALL MARKET SIZE

- 2.1 Global Radioligand Therapy Market Size: 2021 VS 2028
- 2.2 Global Radioligand Therapy Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Radioligand Therapy Players in Global Market
- 3.2 Top Global Radioligand Therapy Companies Ranked by Revenue
- 3.3 Global Radioligand Therapy Revenue by Companies
- 3.4 Top 3 and Top 5 Radioligand Therapy Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Radioligand Therapy Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Radioligand Therapy Players in Global Market
 - 3.6.1 List of Global Tier 1 Radioligand Therapy Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Radioligand Therapy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Used Radionuclides - Global Radioligand Therapy Market Size Markets, 2021 & 2028

4.1.2 Actinium 225 (Ac-225)

4.1.3 Lutetium 177 (Lu-177)

4.1.4 Gallium 68 (Ga-68)

4.1.5 Fluorine 18 (F-18)

4.1.6 Other Radionuclides

4.2 By Used Radionuclides - Global Radioligand Therapy Revenue & Forecasts

4.2.1 By Used Radionuclides - Global Radioligand Therapy Revenue, 2017-2022

4.2.2 By Used Radionuclides - Global Radioligand Therapy Revenue, 2023-2028

4.2.3 By Used Radionuclides - Global Radioligand Therapy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Radioligand Therapy Market Size, 2021 & 2028

5.1.2 Neuroendocrine Neoplasms

5.1.3 Prostate Cancer

5.2 By Application - Global Radioligand Therapy Revenue & Forecasts

5.2.1 By Application - Global Radioligand Therapy Revenue, 2017-2022

5.2.2 By Application - Global Radioligand Therapy Revenue, 2023-2028

5.2.3 By Application - Global Radioligand Therapy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Radioligand Therapy Market Size, 2021 & 2028

6.2 By Region - Global Radioligand Therapy Revenue & Forecasts

6.2.1 By Region - Global Radioligand Therapy Revenue, 2017-2022

6.2.2 By Region - Global Radioligand Therapy Revenue, 2023-2028

6.2.3 By Region - Global Radioligand Therapy Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Radioligand Therapy Revenue, 2017-2028

6.3.2 US Radioligand Therapy Market Size, 2017-2028

6.3.3 Canada Radioligand Therapy Market Size, 2017-2028

6.3.4 Mexico Radioligand Therapy Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Radioligand Therapy Revenue, 2017-2028

- 6.4.2 Germany Radioligand Therapy Market Size, 2017-2028
- 6.4.3 France Radioligand Therapy Market Size, 2017-2028
- 6.4.4 U.K. Radioligand Therapy Market Size, 2017-2028
- 6.4.5 Italy Radioligand Therapy Market Size, 2017-2028
- 6.4.6 Russia Radioligand Therapy Market Size, 2017-2028
- 6.4.7 Nordic Countries Radioligand Therapy Market Size, 2017-2028
- 6.4.8 Benelux Radioligand Therapy Market Size, 2017-2028

6.5 Asia

- 6.5.1 By Region - Asia Radioligand Therapy Revenue, 2017-2028
- 6.5.2 China Radioligand Therapy Market Size, 2017-2028
- 6.5.3 Japan Radioligand Therapy Market Size, 2017-2028
- 6.5.4 South Korea Radioligand Therapy Market Size, 2017-2028
- 6.5.5 Southeast Asia Radioligand Therapy Market Size, 2017-2028
- 6.5.6 India Radioligand Therapy Market Size, 2017-2028

6.6 South America

- 6.6.1 By Country - South America Radioligand Therapy Revenue, 2017-2028
- 6.6.2 Brazil Radioligand Therapy Market Size, 2017-2028
- 6.6.3 Argentina Radioligand Therapy Market Size, 2017-2028

6.7 Middle East & Africa

- 6.7.1 By Country - Middle East & Africa Radioligand Therapy Revenue, 2017-2028
- 6.7.2 Turkey Radioligand Therapy Market Size, 2017-2028
- 6.7.3 Israel Radioligand Therapy Market Size, 2017-2028
- 6.7.4 Saudi Arabia Radioligand Therapy Market Size, 2017-2028
- 6.7.5 UAE Radioligand Therapy Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Novartis

- 7.1.1 Novartis Corporate Summary
- 7.1.2 Novartis Business Overview
- 7.1.3 Novartis Radioligand Therapy Major Product Offerings
- 7.1.4 Novartis Radioligand Therapy Revenue in Global Market (2017-2022)
- 7.1.5 Novartis Key News

7.2 Advanced Accelerator Applications

- 7.2.1 Advanced Accelerator Applications Corporate Summary
- 7.2.2 Advanced Accelerator Applications Business Overview
- 7.2.3 Advanced Accelerator Applications Radioligand Therapy Major Product Offerings
- 7.2.4 Advanced Accelerator Applications Radioligand Therapy Revenue in Global Market (2017-2022)

- 7.2.5 Advanced Accelerator Applications Key News
- 7.3 Mercy Radiology
 - 7.3.1 Mercy Radiology Corporate Summary
 - 7.3.2 Mercy Radiology Business Overview
 - 7.3.3 Mercy Radiology Radioligand Therapy Major Product Offerings
 - 7.3.4 Mercy Radiology Radioligand Therapy Revenue in Global Market (2017-2022)
 - 7.3.5 Mercy Radiology Key News
- 7.4 POINT Biopharma Global Inc
 - 7.4.1 POINT Biopharma Global Inc Corporate Summary
 - 7.4.2 POINT Biopharma Global Inc Business Overview
 - 7.4.3 POINT Biopharma Global Inc Radioligand Therapy Major Product Offerings
 - 7.4.4 POINT Biopharma Global Inc Radioligand Therapy Revenue in Global Market (2017-2022)
 - 7.4.5 POINT Biopharma Global Inc Key News
- 7.5 Fusion Pharma
 - 7.5.1 Fusion Pharma Corporate Summary
 - 7.5.2 Fusion Pharma Business Overview
 - 7.5.3 Fusion Pharma Radioligand Therapy Major Product Offerings
 - 7.5.4 Fusion Pharma Radioligand Therapy Revenue in Global Market (2017-2022)
 - 7.5.5 Fusion Pharma Key News
- 7.6 Telix Pharmaceuticals Ltd
 - 7.6.1 Telix Pharmaceuticals Ltd Corporate Summary
 - 7.6.2 Telix Pharmaceuticals Ltd Business Overview
 - 7.6.3 Telix Pharmaceuticals Ltd Radioligand Therapy Major Product Offerings
 - 7.6.4 Telix Pharmaceuticals Ltd Radioligand Therapy Revenue in Global Market (2017-2022)
 - 7.6.5 Telix Pharmaceuticals Ltd Key News
- 7.7 Lantheus Holdings, Inc
 - 7.7.1 Lantheus Holdings, Inc Corporate Summary
 - 7.7.2 Lantheus Holdings, Inc Business Overview
 - 7.7.3 Lantheus Holdings, Inc Radioligand Therapy Major Product Offerings
 - 7.7.4 Lantheus Holdings, Inc Radioligand Therapy Revenue in Global Market (2017-2022)
 - 7.7.5 Lantheus Holdings, Inc Key News
- 7.8 Bayer AG
 - 7.8.1 Bayer AG Corporate Summary
 - 7.8.2 Bayer AG Business Overview
 - 7.8.3 Bayer AG Radioligand Therapy Major Product Offerings
 - 7.8.4 Bayer AG Radioligand Therapy Revenue in Global Market (2017-2022)

7.8.5 Bayer AG Key News

7.9 Curium Pharma

7.9.1 Curium Pharma Corporate Summary

7.9.2 Curium Pharma Business Overview

7.9.3 Curium Pharma Radioligand Therapy Major Product Offerings

7.9.4 Curium Pharma Radioligand Therapy Revenue in Global Market (2017-2022)

7.9.5 Curium Pharma Key News

7.10 Precirix

7.10.1 Precirix Corporate Summary

7.10.2 Precirix Business Overview

7.10.3 Precirix Radioligand Therapy Major Product Offerings

7.10.4 Precirix Radioligand Therapy Revenue in Global Market (2017-2022)

7.10.5 Precirix Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Radioligand Therapy Market Opportunities & Trends in Global Market

Table 2. Radioligand Therapy Market Drivers in Global Market

Table 3. Radioligand Therapy Market Restraints in Global Market

Table 4. Key Players of Radioligand Therapy in Global Market

Table 5. Top Radioligand Therapy Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Radioligand Therapy Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Radioligand Therapy Revenue Share by Companies, 2017-2022

Table 8. Global Companies Radioligand Therapy Product Type

Table 9. List of Global Tier 1 Radioligand Therapy Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Radioligand Therapy Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Used Radionuclides – Global Radioligand Therapy Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Used Radionuclides - Radioligand Therapy Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Used Radionuclides - Radioligand Therapy Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Radioligand Therapy Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Radioligand Therapy Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Radioligand Therapy Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Radioligand Therapy Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Radioligand Therapy Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Radioligand Therapy Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Radioligand Therapy Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Radioligand Therapy Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Radioligand Therapy Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Radioligand Therapy Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Radioligand Therapy Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Radioligand Therapy Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Radioligand Therapy Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Radioligand Therapy Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Radioligand Therapy Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Radioligand Therapy Revenue, (US\$, Mn), 2023-2028

Table 30. Novartis Corporate Summary

Table 31. Novartis Radioligand Therapy Product Offerings

Table 32. Novartis Radioligand Therapy Revenue (US\$, Mn), (2017-2022)

Table 33. Advanced Accelerator Applications Corporate Summary

Table 34. Advanced Accelerator Applications Radioligand Therapy Product Offerings

Table 35. Advanced Accelerator Applications Radioligand Therapy Revenue (US\$, Mn), (2017-2022)

Table 36. Mercy Radiology Corporate Summary

Table 37. Mercy Radiology Radioligand Therapy Product Offerings

Table 38. Mercy Radiology Radioligand Therapy Revenue (US\$, Mn), (2017-2022)

Table 39. POINT Biopharma Global Inc Corporate Summary

Table 40. POINT Biopharma Global Inc Radioligand Therapy Product Offerings

Table 41. POINT Biopharma Global Inc Radioligand Therapy Revenue (US\$, Mn), (2017-2022)

Table 42. Fusion Pharma Corporate Summary

Table 43. Fusion Pharma Radioligand Therapy Product Offerings

Table 44. Fusion Pharma Radioligand Therapy Revenue (US\$, Mn), (2017-2022)

Table 45. Telix Pharmaceuticals Ltd Corporate Summary

Table 46. Telix Pharmaceuticals Ltd Radioligand Therapy Product Offerings

Table 47. Telix Pharmaceuticals Ltd Radioligand Therapy Revenue (US\$, Mn), (2017-2022)

Table 48. Lantheus Holdings, Inc Corporate Summary

Table 49. Lantheus Holdings, Inc Radioligand Therapy Product Offerings

Table 50. Lantheus Holdings, Inc Radioligand Therapy Revenue (US\$, Mn), (2017-2022)

Table 51. Bayer AG Corporate Summary

Table 52. Bayer AG Radioligand Therapy Product Offerings

Table 53. Bayer AG Radioligand Therapy Revenue (US\$, Mn), (2017-2022)

Table 54. Curium Pharma Corporate Summary

Table 55. Curium Pharma Radioligand Therapy Product Offerings

Table 56. Curium Pharma Radioligand Therapy Revenue (US\$, Mn), (2017-2022)

Table 57. Precirix Corporate Summary

Table 58. Precirix Radioligand Therapy Product Offerings

Table 59. Precirix Radioligand Therapy Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Radioligand Therapy Segment by Used Radionuclides in 2021
- Figure 2. Radioligand Therapy Segment by Application in 2021
- Figure 3. Global Radioligand Therapy Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Radioligand Therapy Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Radioligand Therapy Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Radioligand Therapy Revenue in 2021
- Figure 8. By Used Radionuclides - Global Radioligand Therapy Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Radioligand Therapy Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Radioligand Therapy Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Radioligand Therapy Revenue Market Share, 2017-2028
- Figure 12. US Radioligand Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Radioligand Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Radioligand Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Radioligand Therapy Revenue Market Share, 2017-2028
- Figure 16. Germany Radioligand Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Radioligand Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Radioligand Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Radioligand Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Radioligand Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Radioligand Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Radioligand Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Radioligand Therapy Revenue Market Share, 2017-2028
- Figure 24. China Radioligand Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan Radioligand Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea Radioligand Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia Radioligand Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 28. India Radioligand Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 29. By Country - South America Radioligand Therapy Revenue Market Share, 2017-2028

Figure 30. Brazil Radioligand Therapy Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Radioligand Therapy Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Radioligand Therapy Revenue Market Share, 2017-2028

Figure 33. Turkey Radioligand Therapy Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Radioligand Therapy Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Radioligand Therapy Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Radioligand Therapy Revenue, (US\$, Mn), 2017-2028

Figure 37. Novartis Radioligand Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Advanced Accelerator Applications Radioligand Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Mercy Radiology Radioligand Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. POINT Biopharma Global Inc Radioligand Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Fusion Pharma Radioligand Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Telix Pharmaceuticals Ltd Radioligand Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Lantheus Holdings, Inc Radioligand Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Bayer AG Radioligand Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Curium Pharma Radioligand Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Precirix Radioligand Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Radioligand Therapy Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/R28FE6FC27EAEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R28FE6FC27EAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970